Mutar Study, Phase Ii, Open-Label Study of Erlotinib (E) Treatment in Patients (Pts) with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Mnsclc) Who Present Activating Mutations (Mut plus ) in the Tyrosine Kinase (Tki) Domain of the Epidermal Growth Factor Receptor (Egfr), Assessed the Efficacy of 1L in Portuguese Pts with Mnsclc Egfr Mut